GM-CSF and ipilimumab therapy in metastatic melanoma: Clinical outcomes and immunologic responses

We conducted a phase II clinical trial of anti-CTLA-4 antibody (ipilimumab) and granulocyte-macrophage colony-stimulating factor (GM-CSF) in 22 patients with metastatic melanoma and determined clinical outcomes and immunologic responses. The treatment consisted of a 3-mo induction with ipilimumab at...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Oncoimmunology
Auteurs principaux: Kwek, Serena S., Kahn, James, Greaney, Samantha K., Lewis, Jera, Cha, Edward, Zhang, Li, Weber, Robert W., Leonard, Lonnie, Markovic, Svetomir N., Fong, Lawrence, Spitler, Lynn E.
Format: Artigo
Langue:Inglês
Publié: Taylor & Francis 2015
Sujets:
Original Research
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4839354/
https://ncbi.nlm.nih.gov/pubmed/27141383
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2015.1101204
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires